<DOC>
	<DOC>NCT02511340</DOC>
	<brief_summary>Multi-center, single stage, phase II study to evaluate the efficacy and safety of Flumatinib in accelerated or blastic Phase chronic myelogenous leukemia patients.</brief_summary>
	<brief_title>A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients</brief_title>
	<detailed_description>Multi-center, single-arm, open-label,phase II study to investigate efficacy and safety of Flumatinib in Chinese patients with accelerated or blastic Phase chronic myelogenous leukemia. The starting daily oral dose of Flumatinib is 600mgï¼Œcore test is six cycles (each cycle is 28 days), collecting the core test data for primary efficacy analysis. The longest treatment time is 12 cycles.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<criteria>Male or female patients age 1875 yearold; ECOG 0 2; Newly diagnosed or previously treated Ph+ CML patients in accelerated or blastic Phase; Adequate organ function; Written informed consent prior to any study procedures being performed. Patients in Chronic and Blastic Phases; Previously treated with Flumatinib; Previously documented T315I mutations; Previous therapy within protocol defined timeframe, including: hydroxyurea within 24 hr, Imatinib or Nilotinib or Dasatinib within 28 days) Cardiac dysfunction ; History of congenital or acquired bleeding disorders unrelated to CML; Central nervous system leukemia; Previous malignancy except CML; Acute or chronic liver or severe kidney disease unrelated to CML; Pregnant, breastfeeding, child bearing potential but failed to take effective contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>